SBA Loans for Pharmacy Acquisitions: Complete 2026 Guide

SBA 7(a) for Pharmacy Acquisitions: Loan Sizing and Terms

SBA 7(a) is the default financing structure for independent pharmacy acquisitions in the $500K–$5M range. It offers up to $5M in loan proceeds, 10-year terms for business acquisitions, and flexible collateral requirements that work for goodwill-heavy professional services businesses.

**Current rate environment:** As of mid-2026, SBA 7(a) loans for pharmacy acquisitions are pricing at 8.75%–10.5% all-in (prime rate plus lender spread). On a $1.5M loan at 9.5% over 10 years, monthly debt service is approximately $19,400. Your target pharmacy needs to generate enough EBITDA to cover this at a 1.25x minimum DSCR.

**Loan sizing math:** If your target pharmacy generates $280K EBITDA, maximum supportable debt service at 1.25x DSCR is $224K/year ($18,700/month). At current rates, that supports roughly a $1.44M loan. Equity injection of 10–15% on a $1.6M deal is $160K–$240K. The math determines your purchase price ceiling before you negotiate.

**SBA 504 for pharmacies:** The SBA 504 is primarily for real estate and heavy equipment — it's not the right structure for pharmacy goodwill. Some pharmacy acquisitions involve real estate (owned building), in which case a split structure (504 for real property, 7(a) for business goodwill) can work. Ask your lender about this combination if the pharmacy includes real estate.

Model your deal with the SBA calculator before committing to a purchase price — see our SBA calculator tool to run the numbers.

DEA Registration Timing: The Deal-Critical Constraint

The DEA registration issue is the pharmacy-specific complication that most surprises first-time pharmacy buyers. Plan around it from day one.

**The problem:** In an asset sale (the most common structure), the buyer's new entity needs its own DEA registration to dispense Schedule II–V controlled substances. The seller's DEA registration terminates at close. New DEA applications take 45–90 days, and there is no expedite option.

**Why this matters for SBA financing:** Your SBA lender will want to understand the DEA gap plan before approving the loan. A well-prepared buyer explains: we will close the business acquisition, take possession of assets, and begin dispensing non-controlled medications immediately. We will not dispense controlled substances until the new DEA registration is active. This is legally compliant and operationally feasible — but it means reduced revenue for 45–90 days post-close.

**Financial modeling the DEA gap:** For a pharmacy where 35% of script volume is controlled substances, a 60-day DEA gap reduces revenue by approximately 35% for 2 months. On $1.6M annual revenue, that's a $93K revenue reduction. EBITDA impact depends on whether you can reduce variable costs (staff hours) during the gap period.

**Stock sale alternative:** In a stock sale, the DEA registration remains with the entity and doesn't need to be reissued. This eliminates the DEA gap entirely. For pharmacies with significant controlled substance volume (>30% of scripts), a stock sale is worth the additional complexity. Expect the seller to push for a stock sale anyway — it's better for their tax treatment.

**Structuring around the gap in the purchase agreement:** The purchase price should reflect the DEA gap risk. A reasonable approach: escrow $50K–$75K from the seller's proceeds, released when the new DEA registration is confirmed active. This creates a seller incentive to cooperate fully with the DEA application process.

Equity Injection Requirements: Cash and Seller Note Strategies

Standard SBA 7(a) acquisition loans require a minimum 10% equity injection from the buyer. For goodwill-heavy transactions or buyers with limited industry experience, lenders may require 15–20%. Here's how to structure the equity injection optimally.

**All-cash injection:** The simplest approach. A $1.8M pharmacy acquisition requiring 10% equity = $180K cash from buyer. This is the minimum — and buyers with limited cash reserves should model whether they can fund the first 6 months of operating expenses after the equity injection.

**Seller note as equity injection:** The SBA allows seller notes to count as buyer equity injection if the note is on full standby for 24 months (no principal or interest payments). This is one of the most powerful tools in pharmacy acquisition financing.

Example structure for a $1.8M deal: - SBA 7(a) loan: $1,260,000 (70%) - Seller note on standby: $360,000 (20%) — counts as equity injection - Buyer cash: $180,000 (10%)

The buyer's out-of-pocket at close is $180K instead of $540K. The seller gets a larger portion of proceeds (the note is interest-bearing at 6–7% for years 3–7 after the standby period) but closes the deal. This structure is widely used and lenders who understand it are your best partners.

**Retirement account funding (ROBS):** Some buyers fund equity injection through a Rollover for Business Startups structure, using pre-tax retirement funds to invest in the business. ROBS is legal but administratively complex and adds 4–6 weeks to deal timelines. Use only if you have a qualified ROBS administrator and your deal timeline allows it.

• Confirm lender's minimum equity injection requirement upfront — don't assume 10%
• Model seller note on standby as equity injection to reduce cash out of pocket
• Budget 6 months of working capital reserve beyond the equity injection
• Understand that lender may require personal real estate as additional collateral if equity injection is seller-note-heavy
• ROBS requires 4–6 additional weeks — plan your LOI timeline accordingly

Inventory Valuation at Closing: Cost of Goods, Not Retail

Pharmacy inventory is typically not included in the purchase price — it's handled as a separate transaction at close. Getting this right prevents a common post-close dispute.

**Standard approach:** Conduct a physical inventory count on the closing date or the evening prior. Value inventory at pharmacy cost of goods (what the pharmacy paid), not retail or insurance reimbursement value. The standard reference is wholesaler invoice cost or the National Drug Code (NDC) database pricing.

**Who pays for the physical count:** Split evenly or assigned to one party as a negotiating concession. Third-party pharmacy inventory services (PharMerica, others) can conduct certified counts for $1,500–$3,500 depending on inventory size.

**Typical inventory values:** A 200-script-per-day independent typically carries $80K–$150K in inventory. A 350-script-per-day pharmacy might carry $150K–$250K. Schedule II controlled substance inventory is physically counted separately and documented for DEA compliance.

**Inventory adjustments in the purchase agreement:** Set a target inventory value in the LOI (e.g., $120,000) with an adjustment mechanism: if actual inventory at count is $110,000, buyer pays $10K less; if it's $130,000, buyer pays $10K more. This avoids last-minute negotiation stress at close.

**Expired and near-expired inventory:** Establish a cutoff — inventory within 90 days of expiration is typically not included in the count or is valued at 50% of cost. Controlled substances with less than 30 days of shelf life have specific DEA disposal requirements the seller must address pre-close.

Finding Pharma-Literate SBA Lenders: Why It Matters

This is the most important practical decision in pharmacy acquisition financing, and buyers consistently underestimate it.

A generic SBA lender processes restaurant, retail, and service acquisitions. They understand EBITDA, DSCR, and goodwill underwriting. But they don't understand DEA registration timing, PBM DIR fee accounting, or the controlled substance inventory documentation requirements at close. When these issues arise — and they always do — a non-specialist lender slows down, asks basic questions your attorney has already answered, and sometimes adds conditions that nearly kill deals.

**Lenders with pharmacy experience:** Live Oak Bank has a dedicated healthcare lending vertical with pharmacy acquisition specialists. Lendio, Funding Circle, and several regional CDFIs have closed enough pharmacy deals to have tribal knowledge. Ask any lender you're considering: how many pharmacy acquisitions have you financed in the last 24 months? Who was your most recent pharmacy closing? Get a reference.

**Lender selection process:** Contact 3–4 lenders simultaneously when you're ready to apply. Present them with a summary of the deal — revenue, EBITDA, script count, DEA structure plan, inventory estimate. A lender who gives you a confident, informed response within 48 hours about pharmacies specifically has done this before. A lender who responds with a list of generic SBA checklist questions has not.

For SBA pharmacy financing detail and lender guidance, the SBA pharmacy financing page has additional resources.